Silverback Therapeutics (SBTX) Stock Price, News & Analysis

Company Overview

Silverback Therapeutics, Inc. (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens. Lead candidates are being evaluated in patients with a range of solid tumors, including breast, lung and gastrointestinal cancers. Preclinical studies have demonstrated potent activation of innate immune cells and tumor infiltration, supporting ongoing clinical development.

Founded in 2019 and headquartered in Cambridge, Massachusetts, Silverback Therapeutics completed its initial public offering in 2021. The company’s management team brings experience in oncology drug development and biopharmaceutical innovation, guiding research collaborations and strategic partnerships. Silverback continues to advance its ImmunoTAC platform both independently and through alliances aimed at broadening the reach of its novel immuno-oncology candidates.

Key Stats

• Today's Range: $9.50 to $9.94
• 50-Day Range: $9.41 to $18.35
• 52-Week Range: $2.80 to $8.97
• Volume: 1.63 million shs
• Average Volume: 337,931 shs
• Market Capitalization: $353.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SBTX Stock Analysis - Frequently Asked Questions

How have SBTX shares performed this year?

Silverback Therapeutics' stock was trading at $10.55 at the beginning of 2025. Since then, SBTX stock has decreased by 7.2% and is now trading at $9.79.

How were Silverback Therapeutics' earnings last quarter?

Silverback Therapeutics, Inc. (NASDAQ:SBTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65).

When did Silverback Therapeutics IPO?

Silverback Therapeutics (SBTX) raised $126 million in an initial public offering on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager.

How do I buy shares of Silverback Therapeutics?

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silverback Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silverback Therapeutics investors own include Athenex (ATNX), AbbVie (ABBV), Applied Materials (AMAT), JPMorgan Chase & Co. (JPM), Luminar Technologies (LAZR), Lineage Cell Therapeutics (LCTX) and Aviat Networks (AVNW).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SBTX
• CIK: 1671858
• Web: www.silverbacktx.com
• Phone: 206 456 2900
• Fax: N/A
• Employees: 83
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($2.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.62%
• Return on Assets: -28.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 67.87
• Quick Ratio: 67.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.41 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 36,058,000
• Free Float: 23,654,000
• Market Cap: $353.01 million
• Optionable: Not Optionable
• Beta: 0.60